Bolt Biotherapeutics (BOLT)
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company listed on NASDAQ under the ticker BOLT. The company focuses on developing immunotherapy candidates for cancer, with programs aimed at a range of solid tumors. Its pipeline includes BDC-4182, designed to target claudin 18.2 in cancers such as gastric and gastroesophageal junction cancer and pancreatic cancer; BDC-3042, which is being developed for indications including non-small cell lung cancer and melanoma; CEA ISAC, aimed at tumors that express carcinoembryonic antigen cell adhesion molecule 5; and PD-L1 ISAC, an antibody conjugate intended to engage tumor and immune cells. Bolt Biotherapeutics also has collaboration agreements with Toray Industries, Genmab A/S, and Innovent Biologics, along with a license agreement with Stanford University. The company was founded in 2015 and is based in Redwood City, California.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BOLT
|
$6.43
|
48.4% Upside
|
Undervalued
|
$41
|
845.8% Upside
|
Bargain
|
Fair
|
—
|
—
|
—
|
0.0%
|
August 12, 2026
|
-0.3x
|
0.4x
|
1.3x
|
8.599 M
|
6.727 M
|
72.2%
|
92.2%
|
-14.9
|
—
|
116.9%
|
